PDL Financial Statements From 2010 to 2024

PDL BioPharma financial statements provide useful quarterly and yearly information to potential PDL BioPharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on PDL BioPharma financial statements helps investors assess PDL BioPharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting PDL BioPharma's valuation are summarized below:
PDL BioPharma does not today have any trending fundamental ratios for analysis.
Check PDL BioPharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PDL main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . PDL financial statements analysis is a perfect complement when working with PDL BioPharma Valuation or Volatility modules.
  
This module can also supplement various PDL BioPharma Technical models . Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

PDL BioPharma Company Return On Equity Analysis

PDL BioPharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current PDL BioPharma Return On Equity

    
  -7.36  
Most of PDL BioPharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PDL BioPharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, PDL BioPharma has a Return On Equity of -7.36. This is 69.29% lower than that of the Healthcare sector and 79.81% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably higher than that of the company.

PDL BioPharma Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining PDL BioPharma's current stock value. Our valuation model uses many indicators to compare PDL BioPharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PDL BioPharma competition to find correlations between indicators driving PDL BioPharma's intrinsic value. More Info.
PDL BioPharma is considered to be number one stock in return on equity category among related companies. It is considered to be number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value PDL BioPharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for PDL BioPharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PDL BioPharma's earnings, one of the primary drivers of an investment's value.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as PDL BioPharma using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Other Consideration for investing in PDL Stock

If you are still planning to invest in PDL BioPharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PDL BioPharma's history and understand the potential risks before investing.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Global Correlations
Find global opportunities by holding instruments from different markets
Bonds Directory
Find actively traded corporate debentures issued by US companies
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm